Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (181-190 of 470) with videos related to

Pageof 47
Sort By:
Translational Lung Cancer Research|November 10, 2016
<i>KRAS</i> mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsMónica Garzón, Sergi Villatoro, Cristina Teixidó, et al.
Oncology (Williston Park, N.Y.)|January 20, 2005
The promise of pharmacogenomics: gemcitabine and pemetrexedRafael Rosell, Miquel Taron, Jose Miguel Sanchez, et al.
Drug Design, Development and Therapy|July 26, 2017
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapyMariacarmela Santarpia, Maria Grazia Daffinà, Alessandro D'Aveni, et al.
Cancer Research|July 17, 2004
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancerJulien Mazieres, Biao He, Liang You, et al.
Clinical Lung Cancer|May 8, 2013
A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamicsVassilis Georgoulias, Jean-Yves Douillard, David Khayat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiformeCarme Balaña, Jose Luis Ramirez, Miquel Taron, et al.
Seminars in Oncology|February 26, 2004
Molecular predictors of response to chemotherapy in lung cancerRafael Rosell, Miquel Taron, Aurelio Ariza, et al.
Human Mutation|December 11, 2013
Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residuesMiguel A Molina-Vila, Nuria Nabau-Moretó, Cristian Tornador, et al.
Clinical Lung Cancer|March 5, 2010
Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancerPierre-Jean Souquet, Maciej Krzakowski, Rodrig Ramlau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLCAlain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, et al.
Pageof 47

Showing results (181-190 of 470) with videos related to

Sort By:
Pageof 47
Translational Lung Cancer Research|November 10, 2016
<i>KRAS</i> mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patientsMónica Garzón, Sergi Villatoro, Cristina Teixidó, et al.
Oncology (Williston Park, N.Y.)|January 20, 2005
The promise of pharmacogenomics: gemcitabine and pemetrexedRafael Rosell, Miquel Taron, Jose Miguel Sanchez, et al.
Drug Design, Development and Therapy|July 26, 2017
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapyMariacarmela Santarpia, Maria Grazia Daffinà, Alessandro D'Aveni, et al.
Cancer Research|July 17, 2004
Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancerJulien Mazieres, Biao He, Liang You, et al.
Clinical Lung Cancer|May 8, 2013
A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamicsVassilis Georgoulias, Jean-Yves Douillard, David Khayat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2003
O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiformeCarme Balaña, Jose Luis Ramirez, Miquel Taron, et al.
Seminars in Oncology|February 26, 2004
Molecular predictors of response to chemotherapy in lung cancerRafael Rosell, Miquel Taron, Aurelio Ariza, et al.
Human Mutation|December 11, 2013
Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residuesMiguel A Molina-Vila, Nuria Nabau-Moretó, Cristian Tornador, et al.
Clinical Lung Cancer|March 5, 2010
Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancerPierre-Jean Souquet, Maciej Krzakowski, Rodrig Ramlau, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 23, 2016
Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLCAlain Vergnenegre, Bartomeu Massuti, Filippo de Marinis, et al.
Pageof 47